CMO Summit in Milan, Italy
InvestmentIPOs on course for recovery but does biotech need public funding anymore?IPOs on course for recovery but does biotech need public funding anymore?
2025 will see increased biotech IPOs, spurred on by a “flight to quality” and declining interest rates, says William Blair analyst Kevin Eisele.
Subscribe to Our Newsletters
Stay updated and receive your insights for life sciences investment, innovation and partnering directly in your inbox.